Press Releases

KPS Capital Partners to Sell Attends Healthcare, Inc. to Domtar Corporation for $315 million

Aug 15, 2011

New York, NY (August 15, 2011) -- KPS Capital Partners, LP (“KPS”) announced today that it signed a definitive agreement to sell its portfolio company, Attends Healthcare, Inc. (“Attends” or the “Company”), to Domtar Corporation (NYSE: UFS) (TSX: UFS) for $315 million in cash.

Raquel Palmer, a Partner of KPS, stated, “During our ownership, Attends completed a stunning turnaround and has achieved significant revenue growth year after year. We are proud to be the catalyst for the transformation of Attends, which has resulted in the Company's acquisition by a leading strategic buyer. We congratulate and thank Michael Fagan, Attends’ Chief Executive Officer, and his management team for their strategic vision and brilliant tactical execution. The enormous value created for our investors since we formed the Company in 2007 is the result of their collective effort.”

Michael Fagan, Chief Executive Officer of Attends, added, “KPS was the only investor to recognize the potential value of our business four years ago. Working in partnership with KPS, we quickly executed a remarkable turnaround that formed the foundation for our significant growth. We are very grateful to KPS for its leadership and its commitment to growing our business, which included funding the modernization of our manufacturing platform. We are thrilled to join Domtar, which has the material resources, access to capital and global reach that will enable Attends to reach another level of success.”

Completion of the transaction, which is expected during the third quarter, is subject to customary closing conditions.

Paul Weiss Rifkind Wharton & Garrison LLP served as legal counsel to KPS with respect to the transaction.

About Attends Healthcare, Inc.

Attends Healthcare, Inc. is a leading manufacturer and distributor of a complete line of adult incontinence products for the North American marketplace that are sold primarily under the Attends® brand name. Attends Healthcare primarily serves the non-retail sectors with a focus on the acute care, long-term care, and rapidly growing home healthcare sectors. With over 300 employees, Attends is headquartered in Greenville, NC. For more information please visit www.attends.com.

About KPS Capital Partners

KPS, through its affiliated management entities, is the manager of the KPS Special Situations Funds, a family of investment funds with approximately $19.7 billion of assets under management (as of December 31, 2024). For over three decades, the Partners of KPS have worked exclusively to realize significant capital appreciation by making controlling equity investments in manufacturing and industrial companies across a diverse array of industries, including basic materials, branded consumer, healthcare and luxury products, automotive parts, capital equipment and general manufacturing.  KPS creates value for its investors by working constructively with talented management teams to make businesses better, and generates investment returns by structurally improving the strategic position, competitiveness and profitability of its portfolio companies, rather than primarily relying on financial leverage. The KPS Funds’ portfolio companies currently generate aggregate annual revenues of approximately $22.2 billion, operate 222 manufacturing facilities in 30 countries, and have approximately 58,000 employees, directly and through joint ventures worldwide (as of December 31, 2024, pro forma for recent acquisitions). The KPS investment strategy and portfolio companies are described in detail at www.kpsfund.com.

← Back to Press Releases

footer-logo

One Vanderbilt Avenue, 52nd Floor
New York, NY 10017
T: 212.338.5100 | F: 646.307.7100

KPS does not offer to sell, or solicit offers to purchase, any investment products or securities through any social media platforms or other Internet-based applications (including, but not limited to Twitter (X), Instagram, Facebook, TikTok, WhatsApp, LinkedIn and YouTube).

The information set forth in the materials on this site is as of December 31, 2024 (portfolio company data is as of December 31, 2024, pro forma for recent acquisitions) and does not purport to be a complete summary of KPS or its investments. No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained in such materials. No reliance may be placed for any purpose on the information and opinions contained in such materials or their accuracy or completeness and nothing in such materials may be relied upon in making any investment decision. Certain information on or linked to from this site is furnished by or is derived from materials furnished by outside sources. KPS does not assume responsibility for independent verification of such information and has relied on such information being complete and accurate in all material respects. Any information presented by outside sources represents the understandings and opinions of such outside sources, which may differ from those of KPS. Any statements and quotes from third-parties are not selected on the basis of any performance-based data. Any performance information included in any document on or linked to from this site is presented for illustrative purposes only and is not indicative of the future returns of any of the funds managed by KPS and there can be no assurance that such funds will achieve comparable results, be able to avoid losses or be able to implement their investment strategies.

For information on our data processing practices, please read our privacy policy here.

To read our Diversity, Equity and Inclusion Statement, please click here.

For more information on the “Explanatory Documents for KPS Investors V, Ltd under Article 63-4(3) of Financial Instruments and Exchange Act of Japan” please click here.

For more information on the “Explanatory Documents for KPS Investors VI, Ltd under Article 63-4(3) of Financial Instruments and Exchange Act of Japan” please click here (Form 21-3) and here (Form 20-2).

For disclosures pursuant to the EU Sustainable Finance Disclosure Regulation (SFDR), please click here.